Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Asset Utilization Ratio (2021 - 2025)

Historic Asset Utilization Ratio for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to 0.0.

  • SAB Biotherapeutics' Asset Utilization Ratio fell 10223.81% to 0.0 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.0, marking a year-over-year decrease of 10223.81%. This contributed to the annual value of 0.02 for FY2024, which is 3784.46% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Asset Utilization Ratio of 0.0 as of Q3 2025, which was down 10223.81% from 0.0 recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Asset Utilization Ratio peaked at 0.75 during Q1 2022, and registered a low of 0.0 during Q3 2025.
  • Over the past 5 years, SAB Biotherapeutics' median Asset Utilization Ratio value was 0.13 (recorded in 2023), while the average stood at 0.25.
  • As far as peak fluctuations go, SAB Biotherapeutics' Asset Utilization Ratio soared by 3768.06% in 2022, and later crashed by 10223.81% in 2025.
  • SAB Biotherapeutics' Asset Utilization Ratio (Quarter) stood at 0.61 in 2021, then fell by 24.79% to 0.46 in 2022, then crashed by 91.37% to 0.04 in 2023, then crashed by 32.33% to 0.03 in 2024, then tumbled by 102.17% to 0.0 in 2025.
  • Its Asset Utilization Ratio was 0.0 in Q3 2025, compared to 0.0 in Q2 2025 and 0.01 in Q1 2025.